Health Care Workforce Shortages: An Updated Look
Last week, the Senate Committee on Health, Education, Labor and Pensions held a hearing titled “Examining Health Care Workforce Shortages: Where Do We Go From Here?”
Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
“The patent dance, under current law, places no limits on the number of patents that a branded biologics maker can claim – abusing laws enacted by Congress in 2010 intended to ease biosimilar entry.”
- New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
- MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
- Unintended Consequences of Limiting PBMs
- ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
- 1 big thing: Congress takes on PBMs
- Here comes Humira competition
- Humira Competitors Don’t Guarantee Lower Patient Drug Costs
- The State of Biosimilars: What to Watch
- ‘The Price of Business’: Discussing the Latest Inflation Report
- Alex Brill Interviewed on the Future of the Adalimumab Market
